Ticagrin Tablet 60 mg (Ticagrelor)

Adult dose

This drug should not be used concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180 mg, followed by 90 mg twice daily. Treatment is recommended for 12 months unless discontinuation is clinically necessary. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who have an increased risk of bleeding and have undergone percutaneous coronary intervention (PCI), monotherapy with this drug (discontinuation of aspirin) may be considered after 3 months of concomitant treatment with this drug and aspirin. (See 3. Patients Requiring Caution in Administration.) Patients with a history of myocardial infarction (occurring at least 1 year previously) and at high risk of thrombotic cardiovascular events: Administer 60 mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who took this drug 90 mg or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with this drug at 60 mg. Treatment with this drug may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this drug were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60 mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Refer to the dosage and administration for patients with acute coronary syndrome. Data on the safety and efficacy of this drug for treatment exceeding 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180 mg, followed by 90 mg twice daily for 30 days. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This drug is administered orally and may be taken with or without food. Patients who have difficulty swallowing tablets should crush this drug into a fine powder, disperse it in half a glass of water, and drink the mixture immediately, then rinse the glass used with half a glass of water and drink it again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. When switching from another antiplatelet agent to this drug, start this drug 24 hours after the last dose of the previous medication. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This drug has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age (see “Other” section).

This medication is used to prevent the formation of blood clots by inhibiting platelets from aggregating, thus reducing the risk of thrombotic cardiovascular diseases such as heart attacks and strokes. However, this medication can increase the risk of bleeding, so it should not be administered to patients with active bleeding or a history of bleeding. Patients scheduled for surgery should discontinue this medication at least 5 days prior to the procedure and consult a physician to reduce the risk of bleeding during or after surgery. Patients at high risk for bleeding, such as those who have recently experienced trauma or surgery, have coagulopathy, or a history of gastrointestinal bleeding, should use this medication with caution. This medication should not be used in certain liver impairment patients or those taking strong CYP3A4 inhibitors, and any other medications currently being taken must be disclosed due to potential interactions. Side effects such as dyspnea, bradycardia (slowed heart rate), hyperuricemia, gout, and central sleep apnea may occur; if these symptoms occur, consult a healthcare professional immediately. Pregnant or breastfeeding women should consult a doctor before taking this medication as it may pose risks to the fetus or newborn. The safety and efficacy in children under 18 years have not been established, and it is not recommended for this age group. In cases of overdose, the risk of bleeding increases, and since there is currently no antidote for this medication, immediate emergency care at a medical institution is required. During the course of treatment, dizziness or confusion may occur, so caution is needed when driving or operating machinery. This medication must be stored in its original container, kept out of reach of children, and should not be transferred to another container.

• Hemorrhage
• intracranial hemorrhage
• ocular hemorrhage
• ear hemorrhage
• hypotension
• dyspnea
• respiratory tract hemorrhage
• gastrointestinal hemorrhage
• diarrhea
• nausea

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. The storage temperature should ideally be maintained between 1 to 30 degrees Celsius at room temperature to securely maintain the medication's effectiveness.

Appearance

Pink, round, biconvex, film-coated tablet

Package unit

60 tablets/box [10 tablets/PTP X 6], 30 tablets/box [10 tablets/PTP X 3]